BTAI

BioXcel Therapeutics Inc

Oct 21 • 04:00PM ET

2.20

-0.09 -3.93 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN BIIB INCY NBIX SAGE ACAD ONC EXEL

Index	-	P/E	-	EPS (ttm)	-12.67	Insider Own	3.84%	Shs Outstand	19.65M	Perf Week	-16.03%
Market Cap	43.22M	Forward P/E	-	EPS next Y	-3.05	Insider Trans	0.00%	Shs Float	18.89M	Perf Month	-20.86%
Enterprise Value	133.59M	PEG	-	EPS next Q	-1.02	Inst Own	8.40%	Short Float	8.42%	Perf Quarter	21.55%
Income	-50.95M	P/S	49.68	EPS this Y	79.24%	Inst Trans	1.32%	Short Ratio	0.16	Perf Half Y	30.95%
Sales	0.87M	P/B	-	EPS next Y	37.52%	ROA	-111.70%	Short Interest	1.59M	Perf YTD	-63.23%
Book/sh	-16.26	P/C	2.33	EPS next 5Y	60.31%	ROE	-	52W High	13.28 -83.43%	Perf Year	-75.88%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	28.70% 6.20%	ROIC	-	52W Low	1.17 88.03%	Perf 3Y	-98.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-179.72%	Volatility	7.48% 8.26%	Perf 5Y	-99.74%
Dividend TTM	-	EV/Sales	153.55	EPS Y/Y TTM	77.72%	Oper. Margin	-5655.41%	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.74	Sales Y/Y TTM	-63.88%	Profit Margin	-5869.82%	RSI (14)	34.95	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.76	EPS Q/Q	25.84%	SMA20	-14.10%	Beta	0.22	Target Price	19.80
Payout	-	Debt/Eq	-	Sales Q/Q	-89.13%	SMA50	-37.19%	Rel Volume	0.09	Prev Close	2.29
Employees	37	LT Debt/Eq	-	Earnings	Aug 12 BMO	SMA200	-21.44%	Avg Volume	9.67M	Price	2.20
IPO	Mar 08, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-31.90% -31.43%	Trades		Volume	854,666	Change	-3.93%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-24	Downgrade	UBS	Buy → Neutral	$9 → $4
Aug-15-23	Downgrade	Mizuho	Buy → Neutral	$40 → $4
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold	$20 → $22
Dec-01-22	Upgrade	Goldman	Sell → Neutral	$16
Jul-07-22	Initiated	Mizuho	Buy	$19
Apr-06-22	Reiterated	BofA Securities	Buy	$80
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$55 → $24
Apr-09-21	Initiated	Berenberg	Buy	$75
Feb-01-21	Initiated	UBS	Buy	$99
Oct-30-20	Initiated	Goldman	Buy	$60
Sep-02-20	Initiated	Jefferies	Buy	$82
Aug-17-20	Reiterated	H.C. Wainwright	Buy	$200 → $175
Jul-08-20	Reiterated	H.C. Wainwright	Buy	$95 → $120
Jun-04-20	Initiated	Guggenheim	Buy	$101
Apr-01-20	Initiated	BofA/Merrill	Buy	$45
Feb-26-20	Reiterated	H.C. Wainwright	Buy	$30 → $95
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-12-19	Initiated	SunTrust	Buy	$24

Show Previous Ratings

Oct-14-25 07:00AM	BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes (GlobeNewswire)
Oct-13-25 07:00AM	BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation (GlobeNewswire)
Sep-18-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements (GlobeNewswire)
Sep-10-25 06:30AM	BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Sep-04-25 07:00AM	BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
07:28AM	Loading…
Aug-29-25 07:28AM	BioXCel seeks Igalmi label expansion after Phase III success (Clinical Trials Arena)
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -24.43%
08:00AM	UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
07:00AM	BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
Aug-26-25 04:00PM	BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 (GlobeNewswire)
Aug-19-25 07:00AM	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -13.23%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-13-25 12:33PM	3 Supercharged Stocks Flashing Strong Momentum Signals (Benzinga) -17.65%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Loading…
07:00AM	BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.25%
07:55AM	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +58.42%
07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-08-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.48%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-06-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.78%
07:00AM	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies (GlobeNewswire)
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +85.40%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Jul-21-25 07:00AM	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI (GlobeNewswire)
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-11-25 07:27PM	BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress (Insider Monkey)
07:00AM	Loading…
Jul-01-25 07:00AM	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +8.84%
May-30-25 09:09AM	Real-World Deployments Signal AI Healthcare Is Ready for Scale (PR Newswire)
May-27-25 08:01AM	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
07:00AM	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement (GlobeNewswire)
May-12-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 09:15AM	Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates (Zacks) -7.60%
May-05-25 05:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Mar-27-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.96%
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Mar-20-25 06:50PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 05:10PM	ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.73%
02:13PM	Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight (Zacks)
Mar-11-25 07:00AM	BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -16.84%
Mar-09-25 06:05PM	Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week (Insider Monkey)
Mar-07-25 07:00AM	BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +22.99%
Mar-04-25 04:15PM	BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering (GlobeNewswire) -28.00%
10:00AM	BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Mar-03-25 03:33PM	BioXcel Therapeutics Announces $14 Million Registered Direct Offering (GlobeNewswire) +73.61%
07:00AM	BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia (GlobeNewswire)
Feb-28-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) +24.86%
Feb-06-25 07:00AM	BioXcel Therapeutics Announces Reverse Stock Split (GlobeNewswire) -37.57%
Feb-05-25 07:00AM	BioXcel Therapeutics Provides Clinical and Business Update (GlobeNewswire)
Dec-23-24 12:00PM	BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-22-24 08:16AM	BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -10.80%
Nov-21-24 04:47PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-15-24 02:07AM	BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... (GuruFocus.com) +9.20%
Nov-14-24 11:13PM	Q3 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
08:20AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-13-24 07:31AM	What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings (GuruFocus.com) -6.92%
Nov-12-24 07:00AM	BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia (GlobeNewswire) -7.61%
Nov-08-24 07:00AM	BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-29-24 07:00AM	BioXcel Therapeutics to Present at ThinkEquity Conference (GlobeNewswire) +6.57%
Oct-15-24 07:00AM	BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder (GlobeNewswire) +6.06%
Sep-19-24 07:00AM	BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation (GlobeNewswire)
Sep-12-24 01:22AM	FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares (GuruFocus.com)
Sep-05-24 07:00AM	BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-30-24 09:55AM	BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-07-24 07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.06%
01:31AM	Q2 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 08:10AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 07:00AM	BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire) -6.84%
Jul-16-24 07:00AM	BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +9.84%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
May-28-24 07:00AM	BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 07:00AM	BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-10-24 11:58AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.33%
May-09-24 11:31PM	Q1 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.73%
11:58AM	BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	BioXcel Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-24-24 10:30AM	BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -8.75%
Apr-22-24 07:00AM	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential (GlobeNewswire)
Apr-10-24 07:00AM	BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia (GlobeNewswire)
Mar-25-24 07:00AM	BioXcel Therapeutics Announces $25 Million Registered Direct Offering (GlobeNewswire)
Mar-15-24 07:00AM	BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine (GlobeNewswire) -6.62%
Mar-13-24 08:57AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-12-24 09:48PM	Q4 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-01-24 07:00AM	BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey)
Feb-14-24 08:30AM	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies (GlobeNewswire) +26.02%
Feb-13-24 09:00AM	BioXcel Therapeutics Announces Termination of Proposed Public Offering (GlobeNewswire) +26.15%
Feb-12-24 07:14AM	BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) (GlobeNewswire) -7.58%

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Neill Vincent	See Remarks	Dec 16 '24	Sale	0.35	165	58	19,957	Dec 17 06:10 PM
Mehta Vimal	CEO and President	Dec 16 '24	Sale	0.36	3,117	1,131	59,605	Dec 17 06:08 PM
Steinhart Richard I	Chief Financial Officer	Dec 16 '24	Sale	0.36	577	207	20,932	Dec 17 06:06 PM
Rodriguez Javier	See Remarks	Dec 16 '24	Sale	0.36	430	153	24,423	Dec 17 06:04 PM
Yocca Frank	Chief Scientific Officer	Dec 16 '24	Sale	0.35	430	152	28,931	Dec 17 06:03 PM
O'Neill Vincent	Officer	Dec 16 '24	Proposed Sale	0.35	165	58		Dec 16 04:21 PM
Rodriguez Javier	Officer	Dec 16 '24	Proposed Sale	0.36	430	153		Dec 16 03:59 PM
Yocca Frank	Officer	Dec 16 '24	Proposed Sale	0.35	430	152		Dec 16 03:23 PM
Steinhart Richard I	Officer	Dec 16 '24	Proposed Sale	0.35	438	154		Dec 16 03:00 PM
Mehta Vimal	Officer	Dec 16 '24	Proposed Sale	0.35	983	340		Dec 16 02:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BTAI

BioXcel Therapeutics Inc

Upgrade your FINVIZ experience